Alkermes plc. ALKS

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Ireland, we also have a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.

In October 2025, we and Avadel Pharmaceuticals plc ("Avadel") entered into a definitive transaction agreement, subsequently amended in November 2025 (the "Transaction Agreement"), pursuant to which we agreed to acquire the entire issued and to be issued ordinary share capital of Avadel for consideration of (i) $21.00 per ordinary share, nominal value $0.01 per share, of Avadel (each, an "Avadel Share"), payable in cash at closing and (ii) a non-transferable contingent value right (the "CVR") entitling holders of Avadel Shares to a potential additional cash payment of $1.50 per Avadel Share, contingent upon achievement of a certain specified milestone (the "Avadel Acquisition"). On February 12, 2026, we successfully completed the Avadel Acquisition, adding both LUMRYZ to our portfolio of proprietary commercial products and a commercial organization with experience in narcolepsy.

Last close 43.63 2026-10-23
Market cap $7.32B 2026-06-30 share count
52-week range 27.00 - 55.67

Valuation FY2025 figures against the last close

P/S5.0x
P/E30.5x
P/FCF15.2x
EV/EBITDA26.0x
Dividend yield—
Diluted EPS1.43

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.48B$1.56B$1.66B$1.11B$1.17B$1.04B$1.17B$1.09B$903.4M$745.7M
Cost of revenue $196.5M$245.3M$253.0M$218.1M$197.3M$178.3M$180.4M$176.4M$154.7M$132.1M
Gross profit $1.28B$1.31B$1.41B$893.7M$976.4M$860.4M$990.6M$917.9M$748.6M$613.6M
R&D $324.0M$245.3M$270.8M$272.7M$290.9M$394.6M$512.8M$425.4M$412.9M$387.1M
SG&A $701.5M$645.2M$689.8M$590.8M$549.6M$538.8M$599.4M$526.4M$421.6M$374.1M
Total operating expenses $1.22B$1.14B$1.25B$1.12B$1.08B$1.15B$1.35B$1.19B$1.05B$954.4M
Operating income $254.0M$420.6M$414.1M-$6.1M$97.7M-$112.4M-$175.5M-$99.1M-$147.9M-$208.7M
Interest expense $12.3M$22.6M$23.0M$13.0M$11.2M$8.7M$13.6M$15.4M$12.0M$14.9M
Pre-tax income $291.4M$443.8M$421.5M-$31.1M$87.7M-$96.5M-$197.1M-$127.0M-$143.3M-$214.4M
Income tax $49.8M$71.6M$97.6M$2.0M$11.3M$14.3M$436.0K$12.3M$14.7M$5.9M
Net income $241.7M$367.1M$355.8M-$158.3M-$48.2M-$110.9M-$196.6M-$139.3M-$157.9M-$208.4M
EPS, basic 1.472.222.14-0.97-0.30-0.70————
EPS, diluted 1.432.172.10-0.97-0.29-0.70-1.25-0.90-1.03-1.38
Shares, diluted (wtd. avg.) 168.7M169.2M169.7M163.7M164.8M158.8M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $388.6M$291.1M$457.5M$292.5M$337.5M$273.0M$203.8M$266.8M$191.3M$186.4M
Short-term investments $199.6M$460.5M$316.0M$316.0M$198.8M$362.1M$331.2M$272.5M$242.2M$310.9M
Receivables $334.0M$384.5M$332.5M$288.0M$313.2M$275.1M$257.1M$292.2M$233.6M$191.1M
Inventory $196.6M$182.9M$186.4M$181.4M$150.3M$125.7M$101.8M$90.2M$93.3M$63.0M
Total current assets $1.93B$1.42B$1.49B$1.13B$1.06B$1.11B$962.0M$983.3M$808.8M$790.7M
Property, plant and equipment $221.7M$227.6M$226.9M$222.9M$341.1M$350.0M$362.2M$310.0M$284.7M$264.8M
Goodwill $83.0M$83.0M$83.0M$83.0M$92.9M$92.9M$92.9M$92.9M$92.9M$92.9M
Other intangibles $815.0K$890.0K$2.0M$37.7M$74.0M$111.2M$150.6M$191.0M$256.2M$318.2M
Total assets $2.49B$2.06B$2.14B$1.96B$2.02B$1.95B$1.81B$1.83B$1.80B$1.73B
Accounts payable $108.0M$45.6M$65.6M$32.8M$55.7M$46.0M$54.3M$39.8M$55.5M$46.3M
Short-term debt ——$3.0M$3.0M$3.0M$2.8M$2.8M$2.8M$3.0M$3.0M
Total current liabilities $543.4M$465.2M$520.2M$497.7M$471.3M$438.3M$391.1M$339.8M$291.1M$212.0M
Long-term debt ——$287.7M$290.3M$292.8M$272.1M$274.3M$276.5M$278.4M$280.7M
Total liabilities $667.7M$590.6M$933.5M$920.2M$911.9M$882.7M$720.0M$653.7M$594.4M$516.9M
Retained earnings -$734.8M-$976.5M-$1.34B-$1.70B-$1.54B-$1.49B-$1.38B-$1.19B-$1.04B-$947.9M
Total equity $1.82B$1.46B$1.20B$1.04B$1.11B$1.07B$1.09B$1.17B$1.20B$1.21B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $520.8M$439.1M$401.4M$21.0M$101.7M$82.8M$72.1M$99.3M$19.2M-$63.8M
Depreciation and amortisation $27.2M$28.5M$74.9M$77.9M$78.7M$81.9M$80.4M$103.7M$98.5M$94.3M
Stock-based compensation $98.7M$96.6M$100.9M$94.3M$87.6M$90.2M$101.0M$105.4M$83.9M$94.4M
Capital expenditure $40.4M$33.5M$48.0M$38.3M$28.0M$42.2M$90.9M$69.4M$51.3M$43.7M
Investing cash flow $295.5M-$111.3M$53.4M-$64.5M-$66.2M-$11.5M-$141.8M-$22.2M-$18.4M$127.2M
Financing cash flow $12.4M-$494.1M-$289.7M-$1.6M$29.1M-$2.2M$6.8M-$1.6M$4.1M-$58.2M
Buybacks —$200.3M————————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-143977.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B 2B Revenue, FY2016: 745.7M Gross profit, FY2016: 613.6M Net income, FY2016: -208.4M Revenue, FY2017: 903.4M Gross profit, FY2017: 748.6M Net income, FY2017: -157.9M Revenue, FY2018: 1.1B Gross profit, FY2018: 917.9M Net income, FY2018: -139.3M Revenue, FY2019: 1.2B Gross profit, FY2019: 990.6M Net income, FY2019: -196.6M Revenue, FY2020: 1B Gross profit, FY2020: 860.4M Net income, FY2020: -110.9M Revenue, FY2021: 1.2B Gross profit, FY2021: 976.4M Net income, FY2021: -48.2M Revenue, FY2022: 1.1B Gross profit, FY2022: 893.7M Net income, FY2022: -158.3M Revenue, FY2023: 1.7B Gross profit, FY2023: 1.4B Net income, FY2023: 355.8M Revenue, FY2024: 1.6B Gross profit, FY2024: 1.3B Net income, FY2024: 367.1M Revenue, FY2025: 1.5B Gross profit, FY2025: 1.3B Net income, FY2025: 241.7M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $745.7M $903.4M $1.09B $1.17B $1.04B $1.17B $1.11B $1.66B $1.56B $1.48B
Gross profit $613.6M $748.6M $917.9M $990.6M $860.4M $976.4M $893.7M $1.41B $1.31B $1.28B
Net income -$208.4M -$157.9M -$139.3M -$196.6M -$110.9M -$48.2M -$158.3M $355.8M $367.1M $241.7M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%